Antibody-Drug Conjugates

ADCs have transformed oncology with multiple FDA approvals (Enhertu, Trodelvy, Padcev) and a maturing pipeline. The session covers dual-payload ADC designs, masked and conditionally-activated ADCs, bispecific ADC engineering, antigen-escape resistance mechanisms emerging in solid tumours, novel payload chemistries including topoisomerase-I and DNA-binders, and the regulatory landscape after Daiichi-Sankyo and AstraZeneca platform successes. Discussion addresses ADC manufacturing complexity, biosimilar pathways for first-generation ADCs, the comparison of ADCs against T-cell engagers and bispecifics in similar targets, ADC pharmacokinetics and the role of drug-to-antibody ratio, and emerging targets beyond HER2 and TROP2.